188Re-ImDendrim is an in-situ delivery system made from dendrimer diffusible probes for targeting hypoxic tumoral cells combined with the beta emitter Rhenium-188. 188Re-ImDendrim is composed of a radioactive nitro-imidazole derived ligand loaded with poly-L-lysine Dendrimer. The drug is nicknamed Nanogun.

188Re-ImDendrim was initially developed as a radiolabeled neutral (non-biological) entity to be used in hepatocellular carcinoma in patients who cannot go through direct resection. The indication was recently (2019) extended to patients with unresectable lung malignancies. As such it can be considered as a brachytherapy product.

188Re-ImDendrim’s therapeutic efficacy and safety was evaluated in an experimental liver cancer model (human HCC cell line HegG2) in mice. The molecule entered the first clinical trial in 10 patients with HCC from colorectal cancer in 2017.

Target/Mechanism: Brachytherapy

Leading Emitter: beta electrons (β–)